NEW INHIBITOR BASED ON A QUINOLINE DERIVATIVE Russian patent published in 2023 - IPC C07D215/14 C07D401/14 A61K31/4709 A61K31/501 A61K31/506 A61K45/06 A61P13/12 A61P15/00 A61P17/06 A61P19/02 A61P19/10 A61P27/02 A61P29/00 A61P35/00 A61P9/00 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to a new compound of general formula (I) and a pharmaceutically acceptable salt thereof, which have inhibitory activity against TAM, CSF1R and TRK family kinases. In this formula, W is selected from hydrogen; R is a group represented by the general formula (b): in formula (b) fragment is attached via a linking group to groups M¹ and M²; each of X¹ and X² is independently selected from CR^a and NR^b and X³ is C=O; each of X⁴ and X⁵ is independently selected from C; each of M¹ and M² is selected from hydrogen and C_1-6alkyl, or M¹ and M² together with the atoms to which they are attached, can form a 3-8-membered cycloalkyl; Cy² is selected from 6-14 membered aryl which is optionally substituted with one or more R², each R² being selected from hydrogen, halogen and C_1-6alkyl; Cy³ is optionally substituted with one or more R³; Y², Y³, Y⁶ and Y⁷ are each independently selected from CH or N and at least one of Y², Y³, Y⁶ and Y⁷ is N, with each R³ selected from hydrogen; Cy⁴ selected from optionally substituted with one or more R⁴, Y⁴ and Y⁵ are independently selected from CH or N, and at least one of Y⁴ and Y⁵ is N, ring B is phenyl; each R⁴ is independently selected from hydrogen, -NR^bR^c and C_1-6alkoxy; L is -O, R^b and R^c are absent or in each case each is selected from hydrogen; n is an integer 0-4; in the groups represented by formula (b), is a double bond moiety which is optionally present in the cyclic structure. The invention also relates to a pharmaceutical composition containing a compound of general formula (I) and having the property of an inhibitor of TAM, CSF1R and TRK family kinases, the use of a compound of general formula (I) in the manufacture of drugs for the treatment of diseases associated with the activity of TAM, CSF1R and TRK, a process for the preparation of a compound of formula (I); and an intermediate for its preparation.

EFFECT: obtaining a new inhibitor based on a quinoline derivative.

16 cl, 8 tbl, 24 ex